Resistant Depression - Ketamine Infusion Trial Evaluation

ISRCTN ISRCTN89575054
DOI https://doi.org/10.1186/ISRCTN89575054
EudraCT/CTIS number 2009-016941-25
Secondary identifying numbers 8200
Submission date
21/10/2010
Registration date
21/10/2010
Last edited
27/04/2016
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Dr Rupert McShane
Scientific

Oxford Health NHS foundation trust
Warneford Lane
Headington
Oxford
OX3 7JX
United Kingdom

Email rupert.mcshane@oxfordhealth.nhs.uk

Study information

Study designSingle centre non-randomised interventional phase I treatment trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Can be found at http://www.red-kite.org.uk/id6.html
Scientific titleReD-KITE: Resistant Depression - Ketamine Infusion Trial Evaluation: a phase I, dose escalation, safety study
Study acronymReD-KITE
Study objectivesSeveral recent studies have shown that low dose intravenous ketamine infusion has a dramatic antidepressant effect in patients with treatment resistant depression.

ReDKITE aims to explore this new treatment further, by evaluating the safety and tolerability of repeated ketamine infusions in adult patients of any age with treatment resistant depression. By 'treatment resistant' we mean individuals that have received at least 2 adequate trials of anti-depressants and these have been unsuccessful.

We are interested in:
1. How well a low dose of ketamine is tolerated in people with treatment resistant depression (are there any side effects)
2. Whether ketamine improves mood for people with treatment resistant depression, and if so, how long this can last

Please note that as of 25/10/2012, the anticipated end date of this trial was updated from 01/09/2012 to 31/05/2013.
Ethics approval(s)Oxfordshire REC B approved on the 13th November 2009 (ref: 09/H0605/118)
Health condition(s) or problem(s) studiedTopic: Mental Health Research Network; Subtopic: Depression; Disease: Depression
InterventionAll participants receive the same study drug. In stage 1 participants receive the drug once a week for three weeks and in stage 2 they receive the study drug twice a week for 3 weeks. The study drug is Ketalar® (ketamine) at a dose of 0.5 mg/kg. This is given intravenously over a 40 minute period. Total study duration including follow-up is 3 months 3 weeks.

Study entry: registration only
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase I
Drug / device / biological / vaccine name(s)Ketamine
Primary outcome measureExploring the safety and tolerability of repeated doses of ketamine.

Stage 1:
Measured at baseline, day 0 (-20, 20, 40, 60, 80, 100, 120 and 360 minutes) day 6, day 7 (-20, 20, 40, 60, 80, 100, 120 and 360 minutes), day 13, day 14 (-20, 20, 40, 60, 80, 100, 120 and 360 minutes) day 21, day 28, day 42, day 70 and day 98.

Stage 2:
Measured at baseline, day 0 (-20, 20, 40, 60, 80, 100, 120 and 360 minutes), day 3 (-20, 20, 40, 60, 80, 100, 120 and 360 minutes), day 6, day 7 (-20, 20, 40, 60, 80, 100, 120 and 360 minutes), day 10 (-20, 20, 40, 60, 80, 100, 120 and 360 minutes), day 13, day 14 (-20, 20, 40, 60, 80, 100, 120 and 360 minutes), day 17, day 21, day 28, day 42, day 70 and day 98.
Secondary outcome measuresMonitoring mood.

Stage 1:
Measured at baseline, day 0 (-20, 20, 40, 60, 80, 100, 120 and 360 minutes) day 6, day 7 (-20, 20, 40, 60, 80, 100, 120 and 360 minutes), day 13, day 14 (-20, 20, 40, 60, 80, 100, 120 and 360 minutes) day 21, day 28, day 42, day 70 and day 98.

Stage 2:
Measured at baseline, day 0 (-20, 20, 40, 60, 80, 100, 120 and 360 minutes), day 3 (-20, 20, 40, 60, 80, 100, 120 and 360 minutes), day 6, day 7 (-20, 20, 40, 60, 80, 100, 120 and 360 minutes), day 10 (-20, 20, 40, 60, 80, 100, 120 and 360 minutes), day 13, day 14 (-20, 20, 40, 60, 80, 100, 120 and 360 minutes), day 17, day 21, day 28, day 42, day 70 and day 98.
Overall study start date22/02/2010
Completion date31/05/2012

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsPlanned sample size: 24; UK sample size: 24
Key inclusion criteriaCurrent inclusion criteria as of 25/10/2012:
1. Suffering from Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) major depression (uni-polar or bi-polar)
2. Current or past history of lack of response to two adequate antidepressant trials operationally defined using the Antidepressant Treatment History Form (ATHF)
3. Medically fit to receive ketamine in opinion of Consultant Anaesthetist
4. Aged over 18 years, either sex
5. Willing and competent to give informed consent for participation in the study
6. Good understanding of English
7. If a daypatient, must be accompanied until 6 am on the day after each treatment by a competent adult
8. Participant has previously been assessed by a psychiatrist.
9. Able (in the Investigators opinion) and willing to comply with all study requirements.
10. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study and any clinically significant changes.

Previous inclusion criteria until 25/10/2012:
1. Suffering from Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) major depression
2. Score of 18 or higher on Hamilton Depression Rating Scale (HDRS) at screening and baseline
3. Current or past history of lack of response to two adequate antidepressant trials operationally defined using the Antidepressant Treatment History Form (ATHF)
4. Depression to a level that they are being considered for alternative more intense treatment such as electroconvulsive therapy (ECT)
5. Medically fit to receive ketamine in opinion of Consultant Anaesthetist
6. Aged over 18 years, either sex
7. Competent to consent to research
8. Good understanding of English
9. If a daypatient, must be accompanied until 6 am on the day after each treatment by a competent adult
Key exclusion criteriaCurrent exclusion criteria as of 25/10/2012:
1. Schizophrenia or schizoaffective disorder
2. Dementia or diagnosis of mild cognitive impairment
3. Closed angle glaucoma
4. Individuals with a poor understanding of English
5. Female participants who are pregnant, lactating or planning pregnancy during the course of the study.
6. Participant who is terminally ill
7. Known hypersensitivity to the drug Ketamine
8. Uncontrolled hypertension
9. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study.

Previous exclusion criteria until 25/10/2012:
1. Serious suicide risk as judged by the treating consultant
2. Schizophrenia or schizoaffective disorder
3. History of illegal substance misuse
4. Alcohol dependence in last 2 years
5. Dementia or diagnosis of mild cognitive impairment
6. Antidepressant-induced mania
7. Manic episode in last 2 years
8. Closed angle glaucoma
9. Neuropathic pain
10. On Section of Mental Health Act
11. If daypatient and cannot be accompanied by a competent caregiver
12. Individuals with a poor understanding of english
13. Participant does not have/loses capacity
Date of first enrolment22/02/2010
Date of final enrolment31/05/2012

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Oxford Health NHS foundation trust
Oxford
OX3 7JX
United Kingdom

Sponsor information

Oxford Health NHS foundation trust (UK)
Hospital/treatment centre

Research and Development Department
Warneford Lane
Headington
Oxford
OX3 7JX
England
United Kingdom

Website http://www.obmh.nhs.uk
ROR logo "ROR" https://ror.org/04c8bjx39

Funders

Funder type

Government

National Institute for Health Research
Government organisation / National government
Alternative name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results: 01/06/2014 Yes No
HRA research summary 28/06/2023 No No

Editorial Notes

27/04/2016: Publication reference added